Liu 2019c.

Methods	Study design: Randomised clinical trial Study duration: January 2012 to December 2013 Duration of follow‐up: 5 years Setting: Hospital
Participants	Number of participants: 83 Inclusion criteria: Diagnosed as HCC Age (mean ± SD, range ): TACE + RFA: 57.1 ± 7.5 years; TACE alone: 55.3 ± 7.1 years Male (n/total): TACE + RFA: 25/41; TACE alone: 25/42
Interventions	TACE + RFA group (n = 41) Control group (n = 42)
Outcomes	Tumour response: measured by contrast‐enhanced CT at 1 month after treatment Survival rates: measured at 1, 3, and 5 years after treatment Liver function and the level of AFP: measured by blood testing
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.